Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.63 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.62 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | IL2 | P60568 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28254050 | 0.87 | RAB9A (0.80) | RAB9AMAPTNPC1KDM4EPOLB | |
| SCHEMBL12985924 | 0.81 | NOD2 (0.65) | RAB9AKDM4EPOLBHSD17B10ALDH1A1 | |
| SCHEMBL32659701 | 0.79 | XDH (0.77) | RAB9AMAPTNPC1KDM4EPOLB | |
| SCHEMBL6059766 | 0.79 | RAB9A (0.63) | RAB9AMAPTNPC1KDM4EPOLB | |
| Calycosin SCHEMBL73013 | 0.78 | KDM4E (1.00) | RAB9AMAPTNPC1KDM4EPOLB | |
| Calycosin SCHEMBL30335127 | 0.78 | KDM4E (1.00) | RAB9AMAPTNPC1KDM4EPOLB | |
| SCHEMBL16389295 | 0.78 | RAB9A (0.55) | RAB9AMAPTNPC1KDM4EPOLB | |
| SCHEMBL571161 | 0.77 | RAB9A (1.00) | RAB9AMAPTNPC1KDM4EPOLB | |
| Odoratin SCHEMBL1248967 | 0.77 | PTPN1 (1.00) | RAB9AMAPTNPC1KDM4EPOLB | |
| SCHEMBL29482681 | 0.77 | RAB9A (1.00) | RAB9AMAPTNPC1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091240-B2 | Tubulin binding ligands and corresponding prodrug constructs | OXIGENE, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040044059-A1 | Destroying tumor cell vasculation; antitumor agents; anticancer agents | MATEON THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044059-A1 | Destroying tumor cell vasculation; antitumor agents; anticancer agents | FLT4, TUBB3, FLT1 | RAB9A 3318/4885MAPT 208/4885NPC1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.